Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: QT Testing Services Experts (US)(?)

Council Members in this Study Group: 27

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.Richard Anthony, PhD
Board member
Janus Pharmaceuticals, Inc.

Richard Anthony, PhD, is the Chief Executive Officer at Catalyst Pharma Group, Inc., California, a contract research organization providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies. He also serves as the Board Member of Janus...

1 recent news post(s)
Leo Pavliv, RPh, MBA
VP Operations
Cumberland Pharmaceuticals, Inc.

Leo Pavliv, RPh, MBA, is Vice President Operations at Cumberland Pharmaceuticals in Tennessee. His job responsibilities include directing overall drug development activities for numerous products, regulatory affairs, product development, clinical and non-clinical development, manufacturing, and quality...

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Drugs and Reversible Biologic Antithrombotics | 12-21-2007
Analysis of: Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081 | www.pipelinereview.com
Author: GLG Expert Contributor

vWF is one of a number of attractive antiplatelet targets which include P2Y112, GIIb/IIIa, to name a few. Currently Medicines Company's Cangrelor, a small molecule against P2Y12 is quite far along in development.  In addition, Archemix just published results of its Phase I trial with its anti-vWF...

ACTIVE ANTIDOTE CONTROL is key to safe anticoagulation | 10-15-2007
Analysis of: ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com
Author: GLG Expert Contributor

The IDEAL anticoagulant is: 1. Efficacious - Prevents thrombosis 2. Safe - Low risk of bleeding 3. Titratable - Offers predictable, adjustable, therapeutic effect tailorable to individual patient needs 4. Reversible - Can be actively TURNED OFF if/when necessary (or "dialed down") 5. Convenient - Bolus...

Factors II (Thrombin) and X are not the only places to halt the coagulation cascade | 07-25-2007
Analysis of: Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds | boston.stockgroup.com
Author: GLG Expert Contributor

Factor IX is also a promising target, as it is unique in carrying the coagulation signal from the site of injury with tissue factor activation, to the surface of platelets, where propagation and amplification of coagulation actually occur. REG1 (Regado Biosciences), a highly specific, actively reversible...

PDE-5 class effect on Raynauds may provide evidence that SLx-2101 will work | 07-02-2007
Analysis of: Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease | www.pipelinereview.com
Author: Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.

Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...

remember olestera? (anal leaking) | 06-15-2007
Analysis of: Over-The-Counter Weight Loss Drug Approved | abclocal.go.com
Author: GLG Expert Contributor

does it work?  Is the AE profile translatable to a larger population? 

View All GLG News by members of this Study Group

Most Common Company Types:

  • Pharmaceuticals Manufacturer
  • Academic Medical Center/Hospital or Clinic
  • Consultancy, Pharma-Focused
  • Contract Research Organization, Independent/Small
  • Biotechnology Manufacturer
  • Contract Research Organization, Large
  • Pharmaceuticals/Biotechnology Research Services
  • Consultancy, Healthcare-Focused
  • Medical Device Manufacturer
  • Pharmaceuticals/Biotechnology Research Equipment

Most Common Job Types:

  • Director
  • Chief Medical Officer
  • Physician - Attending Physician
  • Research Scientist
  • Chief Executive Officer
  • Consultant
  • Research & Development Manager
  • Regulatory Analyst
  • Vice President
  • Board Member
  • Operations Executive
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-03T13:45:45.387